The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma

Completed

• Conditions: Pancreatic Neoplasms; Pancreas Cancer

• Registration Number: NCT06553040
• Lead Sponsor: Ege University

Brief Summary

The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01-01
• Primary Completion: 2021-12-01
• Study Completion: 2023-01-01
• Status Verified: 2024-08
• Study First Submitted: 2024-08-10
• Study First Submitted QC: 2024-08-10
• Last Update Submitted: 2024-08-10
• Study First Posted: 2024-08-14
• Last Update Posted: 2024-08-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

• Whipple operation and total pancreatectomy due to pathologically confirmed pancreatic adenocarcinoma

Exclusion Criteria

• Patients with other malignant tumors (choledochal tumor, papilla tumor and duodenal tumor)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival Time	4 Years
LCR Score	4 Years	Lymphocyte / CRP
HALP Score	4 Years	Hemoglobin x Albumin x Lymphocyte / Platelet
Disease-Free Survival Times	4 Years